Aspen Alert’s Post

[update] Samsung Biologics Expand $1B Manufacturing Contract With Undisclosed US Pharma The original contract was based on a a letter of intent with the unnamed client in June of last year (2023), then the scope of the deal has been significantly expanded from the initial agreement in the formal contract. The deal is Samsung Biologics' largest contract ever since its establishment in 2011, according to Korea JoongAng Daily. It also marks the contract manufacturers’ seventh agreement this year, which together amount to $1.8 billion. In 2023, Samsung Bio’s total revenue was around $2.7 billion. For more details 👇 #CDMO #Biologics #antibody #biomanufacturing #businessdevelopment #biopharmaceutical #CMO

#Antibody_Drug_Conjugates_Contract_Manufacturing Market Positioned for Noteworthy Growth During the Assessment Period 2023-2032 https://bit.ly/3ZYNWCh #Antibody drug conjugates #contract manufacturing refers to the #outsourcing of the #production of ADCs to a third-party #manufacturer. This can be an #attractive option for #biotech and #pharmaceutical companies that do not have the #necessary expertise or #resources to produce #ADCs in-house. Sterling RECIPHARM UPPSALA AB Lonza Catalent Pharma Solutions Sartorius AG Microsites Start A Misson WuXi Biologics Samsung Biologics Piramal Group AbbVie Merck KGaA #pharma #manufacturing #antibodies #drugdevelopment #healthcareindustry #drugdelivery

Thoughts on this? >> Lonza buys Genentech facility for $1.2B to boost commercial biologics manufacturing >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharma #pharmaceutical #healthcare #productmarketing

𝐁𝐢𝐨𝐭𝐞𝐜𝐡𝐍𝐨𝐥𝐨𝐠𝐲 𝐂𝐨𝐧𝐭𝐫𝐚𝐜𝐭 𝐌𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠: 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐆𝐫𝐨𝐰𝐭𝐡 𝐚𝐧𝐝 𝐏𝐫𝐨𝐬𝐩𝐞𝐜𝐭𝐬 Global Biotechnology Contract Manufacturing Market was valued US$ 16.5 Bn in 2022 and is expected to reach ~US$ 36.5 Bn by 2032, growing at a CAGR of 8.3% during the forecast period 2023-2032. A Contract Manufacturing Organization (CMO) is a company that specializes in providing services such as drug manufacturing to other businesses within the biopharmaceutical sector. Biotechnology contract manufacturing plays a crucial role in the biopharmaceutical industry by enabling companies to focus on research, development, and commercialization while entrusting specialized partners with efficient and compliant manufacturing processes. Download Research Sample@ https://lnkd.in/dBjwFGHU Top key players: agc inc., Boehringer ingelheim international gmbh, Catalent Inc., emergent, eurofins scientific, fujifilm holdings corporation, genscript biotech corporation, herpalink group, jsr corporation, Lonza, lotte biologics, merck kgaa, recipharm ab, Samsung biologics, stelis, Thermo Fisher Scientific Inc., Wuxi Biologics #BiotechContractManufacturing #BiotechMarketInsights #ManufacturingInnovation #BiotechIndustryTrends #ContractManufacturingGrowth #GlobalBiotechMarket 

Great analysis on the origins of recent pharmaceutical innovation - The analysis indicates that the business model of the top 20 biopharma companies in recent years has largely been built on external innovation, as only 28% of recently FDA-approved drugs were invented and developed internally. Biotech companies were the most important origin of innovation (47% of new drugs) for the top 20 companies. In addition, the internal R&D of the top 20 companies overall has had a stronger focus on small-molecule drugs, and they have accessed the majority of their recently launched biologics from biotech companies. #research #development #innovation #drug #FDA #approval #biopharma #pharmaceutical #biotech https://lnkd.in/g35fRTDy (image: Pharma-Shutterstock)

News: Lonza Acquires Vacaville Pharmaceutical Campus Lonza is investing $1.2 billion to purchase a pharmaceutical manufacturing campus in Vacaville, Calif. Presently occupied by Genentech, a subsidiary of Roche, the 427,000-sf complex provides a total bioreactor capacity of approximately 330 liters. Lonza is offering employment to 750 personnel at the site, which will continue to supply its current products at a committed volume of 30 percent throughout 2025. As the plant transitions to serve alternative customers, an investment of $550 million will upgrade and enhance existing capabilities to support the next generation of mammalian biological therapies. https://lnkd.in/d5tJwMtK #researchanddevelopment #biomedical #pharmaceutical #biotechnology #manufacturing #adaptivereuse #modernization

Did you know MMC was once considered impossible to synthesize? The inception of Disruptive Pharma was sparked by the discovery of MMC technology in 2012 at Uppsala University by professor Maria Strömme and her group. This breakthrough in synthesizing a novel form of magnesium carbonate, previously thought impossible, marked the beginning of our journey. With exclusive rights to this technology for pharmaceutical applications and two pending patent families, we are at the forefront of drug delivery innovation. Our long-term ambition is not only to dominate the market for drug formulations but also to revolutionize how drugs are developed and delivered. By offering solutions that improve solubility, enhance bioavailability, and reduce the need for excipients, we are setting new standards in the pharmaceutical industry. #drugdelivery #formulation #bioavailability #solubility

Thoughts on this? >> Lonza buys Genentech facility for $1.2B to boost commercial biologics manufacturing >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #productmarketing #pharmaceutical #pharma #healthcare

💲 $1.5 billion deal that makes up 39% of last years sales.... 2 key takeaways: 1. The projected growth for the CDMO market over the next 10 years is only fueled by deals like this - and Samsung Biologics is continuing to make some serious waves. 2. Someone is getting a healthy bonus. #cdmo #industry #pharmaceutical #manufacturing

Corden Pharma - A Full-Service CDMO has announced its largest strategic investment to date with a committed spend of ~€900m over the next 3 years to grow its Peptide technology platform. These transformational plans consist of two major expansion initiatives occurring in parallel in the #US and #Europe, including both existing facilities and new constructions designed and built according to the pharmaceutical industry’s most stringent quality and technical standards for short and long peptide manufacturing, including Biologics License Applications (BLA) requirements. The US expansion involves bringing additional Peptide capacity to the CordenPharma Colorado site with the planned #construction of a new large-scale manufacturing facility, and an additional increase in manufacturing trains in the existing facility. The European expansion centers on the construction of a new state-of-the-art greenfield facility, with the aim of creating additional Peptide capacity to serve customers from initial early clinical to late-stage #commercial manufacturing. Judith Charpentier, Dr. Signe Michel, Michael Quirmbach To share your startup story write us on - contact@startuprise.co.uk #CordenPharma #investment #technology #pharmaceutical #commercial